Introduction
Atrial fibrillation/flutter (AF) is the most common cardiac arrhythmia with substantial impact on morbidity and mortality as well as increasing incidence and prevalence. 1 In clinics, restoring sinus rhythm is the first goal to relieve the patients from their symptoms and electrical cardioversion has the highest efficacy in acutely terminating AF. However, electrical shocks require high electrical currents inducing substantial pain and patient discomfort and can damage the heart. 2 Therefore analgosedation is indispensable and miniaturized implantable 'atrioverter' are generally not accepted by the patients. 2 Thus, electrical overdrive pacing with well-tolerable electrical currents, so called anti-tachycardia pacing was developed, 3 but turned out to be ineffective in terminating AF episodes with short and irregular cycle lengths. 4 Hence, an effective and pain-free therapeutic approach for AF termination on demand is currently lacking.
In clear contrast to electrical field stimulation, optogenetics allows selective stimulation of defined cell types, which were genetically engineered to express light-sensitive proteins. 5 The light-gated non-selective cation channel Channelrhodopsin-2 (ChR2) has been applied before for ventricular and atrial pacing of intact mouse hearts by short light pulses. 6, 7 Importantly, ChR2 expression could be restricted to cardiomyocytes, allowing light-induced pain-free stimulation without side effects. Furthermore, optogenetics provides the advantage of uniform and sustained depolarization which results in refractoriness of cardiomyocytes 6 and this was recently used to terminate re-entrant electrical wavefronts in a monolayer of neonatal, atrial rat cardiomyocytes in vitro. 8 To investigate if optogenetic methods could be used to terminate AF in the complex 3D architecture of intact atria, we sought to establish optogenetic cardioversion in the murine heart. Here we demonstrate for the first time, that epicardial illumination is a highly reliable approach to terminate AF in ChR2 expressing transgenic mice and in wild type mice after adeno-associated virus (AAV)-mediated gene delivery.
Methods

Animals
All animal experiments were carried out according to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and were approved by the National Office for Nature, Environment and Consumer Protection in Recklinghausen, Nordrhein-Westfalen (Permit Numbers: 84-02.04.2015.A267 and 84.02.04.2011.A292).
A new optogenetic AF-susceptible mouse line was generated by crossing mice expressing ChR2 with the H134R mutation 9 under control of the chicken b-actin (CAG) promoter 6 with mice carrying a targeted heterozygous Ala96Ser mutation of the mouse Connexin 40 gene (Cx40 Ala96Ser).
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ChR2 mice had CD1 genetic background (backcrossed at least 10 generations) and Cx40 Ala96Ser mice had C57/Bl6 background (backcrossed at least 10 generations). For ex vivo Langendorff perfusion of explanted hearts, we used ChR2 positive/Cx40 Ala96Ser (þ/-) mice (n = 17, 47% female, 31 ± 4 weeks), ChR2 negative/Cx40 Ala96Ser (þ/-) mice (n = 6, 17% female, 51 ± 1 weeks), CD1 wild type mice (n = 9, 78% female, 58 ± 5 weeks) and CD1 wild type mice after AAV-mediated gene transfer (n = 7, all female, 45 ± 1 weeks). For in vivo stimulation we used ChR2 positive/Cx40 Ala96Ser (þ/-) mice (n = 3, 1 female, 18 ± 3 weeks).
AAV-based gene transfer
The AAV9-CAG-hChR2(H134R)-mCherry virus (AAV9 capsid and AAV2 DNA) was obtained from Penn Vector Core (University of Pennsylvania, PA, USA). 2 Â 10 11 genome copies diluted in 100 ml phosphate buffered saline (PBS) were injected systemically via the internal jugular vein of 10-week-old female CD1 wild type mice (Charles River Laboratories, Wilmington, MA, USA) as described earlier. 7, 11 Mice were analyzed ex vivo 29 (n = 2), 36 (n = 3), and 37 (n = 2) weeks after virus injection at a mean age of 45 ± 1 weeks. For quantification of viral transduction, the right atria were dissected after the experiments and incubated in collagenase B (1 mg/ml; Roche, Basel, Switzerland) for 30 min at 37 C and shaken at 500 rpm. Subsequently cells were dissociated by pipetting, centrifuged (10 min, 5000 rpm), re-suspended in Tyrode's solution and plated on laminin coated glass cover slips, for counting by fluorescence microscopy (10Â objective, numerical aperture (NA): 0.3, Zeiss, Jena, Germany). At least five fields of view per heart were analyzed for the percentage of mCherry positive cells as earlier reported. 7 The remaining heart with the intact left atrium was used for histological analysis (see below).
Ex vivo Langendorff-perfused hearts
The experimental setup is summarized in Figure 2A . inserted via the orifice of the superior vena cava into the right heart chambers ( Figure 2A ). Epicardial illumination of the atria was performed with a macroscope (MVX10, Olympus, Tokyo, Japan) and a 1Â objective (MVLPAPO1x, NA: 0.25) using a light-guide (Ø 3 mm) coupled 470 nm LED and a constant current driver (GCS-0470-50-A0510 and BLS-13000-1, Mightex, Pleasanton, CA, USA) controlled by the PowerLab system and the LabChart software. The area of illumination was set with the zoom function of the macroscope to circles of 100, 26, or 10 mm 2 in order to cover both atria, the whole right atrium and parts of the right atrium, respectively ( Figure 2A) . A powermeter (PM100, Thorlabs, Newton, NJ, USA) was used to calculate the light intensity (light power divided by illuminated area in mW/mm 2 ). After establishment of a regular sinus rhythm, we performed in some experiments an illumination protocol with light pulses of 3 s duration and stepwise increasing light intensity ($0.02 mW/mm 2 increase per step, 2 s delay in-between). Thereby we analyzed the individual lowest light intensities for induction of a premature supraventricular contraction (PSVC) and for complete local block of atrial electrical activity, which was defined as absence of atrial signals in the local atrial electrogram. To determine the atrial refractory period (ARP), programmed atrial electrical stimulation with shortening of one extra S2 stimulus (6Â S1 with 150 ms cycle length, 1Â S1S2 decreased by 2 or 3 ms each step) was performed with constant current applied slightly above the pacing threshold (stimulator 2100, AM Systems, Sequim, WA, USA) through bipolar silver chloride electrodes placed epicardially on the right atrium. ARP was defined as shortest S1S2 with effective atrial response in the electrograms. To increase the susceptibility to sustained episodes of atrial tachyarrhythmia (>15 s), perfusion solution was changed to a modified Tyrode's solution with low potassium concentration (2 mM) constantly supplemented with 300 mM Diazoxide. To detect the effect of this perfusion solution, we waited for at least 7 min and reanalyzed P-wave duration as well as ARP.
In this condition, electrical atrial burst stimulation (duration: 5 s, cycle length: 10-50 ms, current: 1-10 mA) reliably induced atrial flutter or fibrillation (AF) episodes characterized by high-frequency atrial electrical activity and a regular (atrial flutter) or irregular (atrial fibrillation) ventricular activation. The dominant cycle length of the respective arrhythmia was calculated from extracardiac or intracardiac electrograms.
To determine success rates of optogenetic cardioversion and to compare different illumination parameters, only AF episodes lasting for at least 3 s after electrical burst stimulation were analyzed in order to exclude shorter self-terminating AF episodes ( Figure 2C) . In each attempt 4 light pulses of identical illuminated area (10, 26, and 100 mm ) and pulse duration (1, 3, 10, 30 , 100, 300, and 1000 ms) were applied with 1 s delay in between. AF termination between the first light pulse and 3 s after the last light pulse ( Figure 2C ; highlighted as green box) was defined as successful optogenetic cardioversion. If AF persisted, the attempt was classified as nonsuccessful and high intensity illumination (up to 5 mW/mm 2 ) was applied to terminate AF, allowing subsequent cardioversion attempts in the same heart. If AF still persisted, perfusion was temporally changed to normal Tyrode's solution until AF ceased. For statistical analysis of success rates, each illumination setting was tested for at least five attempts and the average success rate of each individual heart was used for comparison and is displayed as one data point in the figures. For mechanistic insights, we classified AF termination by light into three categories: (i) direct block, defined as cessation of high frequent atrial electrical activity exactly with onset of illumination or within one AF cycle thereafter, (ii) termination during, or (iii) after the illumination. To allow comparison to spontaneous AF termination, we analyzed and classified AF terminations likewise in ChR2 positive and ChR2 negative hearts using the identical illumination protocol (1 s, 0.4 mW/mm 2 , 100 mm 2 ). Hearts of CD1 wild type mice with or without AAV-injection had shorter episodes of AF, most likely due to the lack of the Cx40 Ala96Ser mutation. Therefore, a one light pulse (1 s, 5 mW/mm 2 , 100 mm 2 ) protocol was used for statistical analysis of cardioversion success rates (effective AF termination between onset and 1 s after the first light pulse).
For some noisy electrogram recordings, a low pass filter of 70-90 Hz was applied.
In vivo electrophysiological investigation and optogenetic cardioversion
Thirty minutes prior to the procedure, buprenorphine (0.1 mg/kg) was subcutaneously injected for intraoperative analgesia. Anaesthesia was induced by 1.5-2.5 vol.% isoflurane in 50% N 2 O/50% O 2 . Mice were intubated and ventilated (MINIVENT Mouse Ventilator Type 845, Harvard Apparatus Inc., Holliston, MA, USA) and placed on a warming plate (37 C) . The right jugular vein was dissected from surrounding tissue and the 2-French octapolar mouse electrophysiological catheter (see above) was inserted and advanced into the right heart chambers as previously reported. 10 Bipolar electrograms between neighboring electrodes showed atrial (proximal electrodes) or ventricular signals (distal electrodes). Subsequently the rib cage was carefully surgically removed and the heart exposed as described before. 6, 7 A spoon was placed below the heart's apex for stabilization and to expose the atria for illumination. A 'surface' ECG was recorded between the right front leg and the spoon using the PowerLab system (see above). Illumination of the anterior portion of both atria ($100 mm 2 ) was performed with a macroscope (see above). AF was induced by intra-atrial burst stimulation using the proximal electrode pairs of the intracardiac catheter showing clear atrial signals (duration: 5 s, cycle length: 10-50 ms, current: 1-3 mA). After the experiment mice were sacrificed by cervical dislocation.
Histology and immunofluorescence
Epicardial mCherry fluorescence was determined with a MVX10 macroscope (1Â objective, NA: 0.25) using a mCherry filter set (F36-504, AHF Analysentechnik, Tübingen, Germany), a calibrated light source system (X-Cite 120 PC, Lumen Dynamics, Mississauga, Ontario, Canada), and an EMCCD camera (iXon 885þ with Solis software, Andor Technology, Belfast, United Kingdom). Explanted hearts with intact left atria were perfused with and stored in 4% paraformaldehyde for 24 h, subsequently dehydrated in 20% sucrose and frozen. Sections were cut with a cryotome (10 mm; Cryostat CM3050 S, Leica, Wetzlar, Germany). Staining and image acquisition were performed as reported earlier. 
Statistical analysis
Data are shown as mean ± standard error of the mean. Statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). P-wave duration and ARP before and after changing to Tyrode's solution with 2 mM potassium and 300 mM Diazoxide as well as between ChR2 positive and ChR2 negative hearts were compared using the two-way repeated measures ANOVA with Bonferroni posttest ( Figure 1B and C). The arrhythmia cycle lengths in ChR2 expressing and non-expressing hearts were compared using the Chi-square test for trend. Success rates with and without illumination in ChR2 expressing versus ChR2 non-expressing hearts were compared using the one-way ANOVA Kruskal-Wallis with Dunn's multiple comparison post-test because of the non-normal distribution of each parameter tested and unequal variances of average cardioversion success rates. The differently classified AF terminations were compared between ChR2 positive and ChR2 negative hearts using the Chi-square test. The effect of different illumination parameters (illuminated area, light intensity and light pulse duration) was tested using the Friedman with Dunn's multiple comparison post-test because of the non-normal distribution, unequal variances and the repeated measures in identical hearts. A P-value < 0.05 was considered statistically significant. Asterisks in the figures indicate significant levels (*P < 0.05; **P < 0.01; ***P < 0.001).
Results
Establishing AF induction and optogenetic cardioversion in the isolated perfused mouse heart
Because analysis of optogenetic cardioversion requires sustained episodes of AF, we took advantage of a mouse model carrying the lossof-function Cx40 Ala96Ser mutation. These mice were crossed with transgenic mice expressing the ChR2 H134R variant 9 under control of the ubiquitous chicken b-actin promoter with a CMV enhancer element resulting in particularly strong transgene expression in all 6, 12 Hearts from ChR2 positive/Cx40 Ala96Ser (þ/-) or ChR2 negative/Cx40 Ala96Ser (þ/-) offspring were explanted and retrogradely perfused in Langendorff configuration. After regular sinus rhythm was observed the ARP and P-wave duration was determined. Subsequently the external solution was changed to a modified Tyrode's solution with low K þ (2 mM) concentration supplemented with the K ATP -channel activator Diazoxide (300 mM). While basic electrophysiological properties of the atria were not different between ChR2 negative or ChR2 positive hearts, the modified Tyrode's solution caused a prolongation of the P-wave duration ( Figure 1A and 1B) indicating reduction of conduction velocity in the atria, and a shortening of the ARP ( Figure  1C ) indicating reduction of action potential duration. Both effects would lead to a decreased cardiac wavelength (conduction velocity * refractoriness), which is the most important factor for micro-re-entrant waves in cardiac tissue. 13 In consequence, bipolar epicardial electrical burst stimulation (5 s, cycle length 10-50 ms, 1-10 mA) of the right atrium was able to reliably induce sustained episodes (> 15 s) of atrial flutter ( Figure 1D top) or atrial fibrillation ( Figure 1D bottom) characterized in accordance to clinical decision criteria by high-frequency atrial electrical activity and regular or irregular ventricular activation, respectively. Since atrial flutter was only observed in 17.2% of ChR2 positive (n = 238 episodes) and in 17.9% of ChR2 negative hearts (n = 223 episodes), we merged atrial flutter and fibrillation in one AF group for statistical comparisons. The majority of AF episodes had a predominant cycle length between 30 and 70 ms which were equally distributed and not different between ChR2 positive and negative hearts ( Figure 1E ).
Efficacy of optogenetic cardioversion
For optogenetic cardioversion, blue light (470 nm, 1 s, 0.4 mW/mm 2 , 100 mm 2 ) was focused onto the epicardial surface of both atria ( Figure  2A) , which terminated AF in all ChR2 expressing hearts (n = 17; Figure  2B ). To determine cardioversion efficacy, we developed an illumination protocol using four consecutive light pulses (1 s, 0.4 mW/mm 2 , 100 mm 2 ) and 1 s delay in-between ( Figure 2C) with the rationale that, in contrast to electrical shocks, multiple light stimulations are technically feasible. Analysing all AF episodes (n = 101) from ten ChR2 positive hearts, the AF termination efficacy after the first and second light pulse was already 91 and 98%, respectively whereas these values were only 13 and 25% in all AF episodes (n = 114) of six ChR2 negative hearts ( Figure 2D) . Importantly the overall average success rate per heart after the four light pulse protocol was 96.5 ± 3.5% for optogenetic cardioversion in ChR2 positive hearts (n = 17), whereas control experiments revealed significantly lower spontaneous conversion rates with an average of 43.1 ± 4.8% in ChR2 positive hearts within the identical timeframe but without illumination (n = 10) and of 54.9 ± 9.2% in ChR2 negative hearts with the same illumination protocol (n = 6) ( Figure 2E and Supplementary material online, Figure S1A -C). This indicates that ChR2 expression and illumination are required for optogenetic cardioversion.
In addition, the identical spontaneous conversion rates in both control groups exclude altered electrophysiological behaviour and influence on spontaneous AF termination by ChR2 expression alone.
Mechanism of optogenetic cardioversion
To investigate which illumination parameters affect optogenetic cardioversion, we performed the same protocol but altered the size of tion. An electrogram was recorded with electrodes (grey) placed at the right atrium and at the apex of the heart. In some experiments an octapolar electrophysiology catheter was additionally introduced via the superior vena cava into the right heart chamber (dark grey). AF was induced by electrical burst stimulation with an atrial electrode pair (red). Circular illumination was performed with a blue LED (470 nm) focused on the epicardial atrial surface at three different sizes covering both atria (100 mm 2 , light blue), the whole right atrium (26 mm illumination, the light intensities and the pulse durations. We found a significant influence of the size of the illuminated area ( Figure 3A ) and the applied light intensity ( Figure 3B ) on efficacy, indicating that affecting a critical area of the atria and also deeper myocardial cell layers is important for successful optogenetic cardioversion. Furthermore, efficacy was lower when reducing the pulse duration to 10 ms and close to spontaneous termination rate when using 3 or 1 ms pulses ( Figure 3C ) highlighting that illuminations longer than the AF cycle length (30-70 ms, Figure 1E ) are important. To further delineate the differences between spontaneous conversion and optogenetic cardioversion, we classified AF termination in ChR2 positive ( Figure 3D ) and ChR2 negative mice (Supplementary material online, Figure S1B and C) into AF episodes (i) blocked directly with onset of illumination ( Figure 3D top) , (ii) terminating during the light pulse ( Figure 3D middle and Supplementary material online, Figure S1B ), or (iii) terminating after illumination ( Figure 3D bottom and Supplementary material online, Figure S1C ). In ChR2 expressing hearts over 80% of AF episodes were terminated directly with onset of illumination (direct block) whereas in ChR2 non-expressing hearts, AF episodes terminated predominantly (>90%) during or after the illumination ( Figure 3E) . To determine possible cardioversion mechanisms, we applied light pulses of increasing intensities to both atria during sinus rhythm and analysed local atrial electrograms. In all hearts tested, light intensities as low as 0.05 mW/mm 2 were sufficient to evoke atrial excitation indicated by light-induced PSVC ( Figure 4A and C) . In principle, such local excitation of the atria could terminate AF by a mechanism termed 'filling of the excitable gap' (see discussion). In contrast, higher light intensities were able to induce a total block of atrial electrical activity indicated by lack of electrical signals within atrial recordings ( Figure 4B and C) . During AF, this would result in a block of electrical activity within re-entrant waves.
Optogenetic cardioversion in vivo
To demonstrate the feasibility of optogenetic AF termination in vivo, we intubated and ventilated mice and performed an 'open chest' preparation 6, 7 terminated AF in all mice tested (n = 3 mice; Figure 5 ). These results prove the feasibility of optogenetic cardioversion by epicardial illumination in vivo, despite the fact that hemoglobin in the atrial wall absorbs light and impairs light penetration.
14 In addition, hearts were illuminated through the pericardial sack which adds another tissue layer the light has to penetrate. 
Optogenetic cardioversion in wild type hearts
Because of the tantalizing possibility of optogenetic cardioversion in patients, we assessed the feasibility in non-transgenic hearts after viral gene transfer for ChR2 expression, which is a prerequisite for clinical applicability. We previously reported long-lasting ventricular ChR2 expression in mouse hearts after one systemic injection of AAV, which was sufficient for optogenetic pacing 7 and defibrillation of ventricular tachycardia and fibrillation. 11 To show long-lasting expression of ChR2 also in the atria, we analyzed hearts 6-8 months after injecting AAV expressing ChR2 in fusion to mCherry. We found bright mCherry signals in epicardial images of the atria ( Figure 6A ) and no obvious adverse side effects, such as wall thinning ( Figure 6B ). Detailed histological analysis revealed the presence of CD45-positive immune cells within the atrial Figure S2A and B). However this had no influence on cardiomyocyte survival because we could not detect any TUNELpositive apoptotic cardiomyocytes and gap junctions were similar distributed in the atria of AAV-transfected and control hearts (Supplementary material online, Figure S2C-F) . Expression of mCherry was equally distributed throughout the whole atrial wall ( Figure 6C ) and localized within the membrane of the expressing cardiomyocytes ( Figure 6D) . AF episodes were induced in explanted hearts as reported above and were shorter than in Cx40 Ala96Ser (þ/-) mice but lasted for at least 5 s. Thus we compared the efficacy of a single light pulse to the spontaneous conversion rate in the same timeframe in AAV transduced hearts without illumination and in CD1 wild type hearts with the same illumination protocol. We found that illuminating (1 s, 5 mW/mm 2 , 100 mm 2 ) the epicardium of both atria ( Figure 7A ) terminated AF with an average efficacy of 74.7 ± 9.1% (n = 7) in AAV transduced hearts. This was significantly higher than the spontaneous conversion rate in these hearts (9.1 ± 3.8%; n = 7) and the termination rate in hearts from non-transduced wild type mice using the same illumination protocol (24.7 ± 5.9%; n = 9) ( Figure  7B) . After the experiments, we dissociated the right atrium and determined the percentage of ChR2 expressing atrial myocytes ( Figure 7B ). This value correlated well with the success rates of cardioversion and importantly suggested that one heart could not be cardioverted because of the low expression rate (8%).
Discussion
We herein present a novel protocol to induce sustained episodes of AF in mouse hearts using three perturbations of atrial electrophysiology: (i) Cx40 is the predominant atrial connexin isoform and the human Ala96Ser mutation was demonstrated to increase susceptibility for AF in patients. 15 In the mouse model this mutation led to a decreased P-wave amplitude, prolonged P-wave duration and decreased atrial conduction velocities compared with wild type mice. 10 (ii) Opening of K ATP -channels with Diazoxide shortens action potential duration and 16, 17 which is one key component of electrical remodelling during AF. 18, 19 (iii) Low K þ is known to increase the susceptibility for AF in patients. 20 Interestingly, we were able to detect that this combined approach led to prolonged P-waves and thus further slowed atrial conduction velocity. Altogether, these measures will reduce the cardiac wavelength enabling the accommodation of re-entrant waves in the small mouse atrium. In accordance, this allowed not only to provide the first evidence for optogenetic cardioversion of AF but also to determine the AF termination efficacy with various illumination parameters. Importantly, ChR2 overexpression per se did not affect atrial electrophysiology or AF stability, which is suggested by unaltered P-wave duration, ARP and similar spontaneous AF termination rate in ChR2 expressing and non-expressing hearts. Three possible mechanisms could underlie the observed optogenetic AF termination: (i) Similar to pharmacological approaches, constant optogenetic depolarization could modulate atrial conduction, excitability or refractoriness and thereby modify AF activity within the atrium, eventually leading to colliding and self-extinction of re-entrant waves. Such a 'modulatory mechanism' was proposed in one of the recent reports on optogenetic defibrillation, which suggested light-induced prolongation of action potentials as the underlying mechanism. 21 However, because AF terminated in most (>80%) of cases directly at onset of illumination ( Figure 3E ), we consider this mechanism of minor importance.
(ii) Light pulses could induce action potentials in the excitable parts of the atrium on the trailing edge of the re-entrant wave and thereby create new excitation waves that collide with the re-entrant AF waves. Such a mechanism is termed 'filling of the excitable gap' and is considered to be the underlying mechanism of anti-tachycardia pacing by electrical stimulation, which has a low efficacy in patients. 4 This is most likely due to the fact that the excitable gaps are small in AF and thus difficult to be filled all ; blue circle; n = 7) compared with spontaneous termination during the same time window without illumination (grey squares; n = 7) and to hearts from untreated wild type mice with the same illumination protocol (grey triangles; n = 9). Kruskal-Wallis test: P = 0.0010; asterisks indicate the significances of Dunn's multiple comparison post-test. The percentages of atrial cardiomyocytes expressing ChR2 are indicated next to the AF termination rate of the corresponding heart. Due to a technical problem during the dissociation of one heart, percentage values could only be obtained for six hearts.
at once with non-triggered random pacing. In line with this, we observed low AF termination efficacy using brief light pulses (1-10 ms, Figure 3C ) applied to one atrium although the intensity used is above the pacing threshold ( Figure 4A and C) . Thus reliable filling of the excitable gaps by optogenetic stimulation would require local illumination triggered after the trailing edge of re-entrant waves or global illumination affecting all fibrillating regions, 22 which is both technically challenging. (iii) Sustained and higher intensity illumination can constantly depolarize cardiomyocytes, 6 ,11 which would not only fill the excitable gap but also keep the illuminated tissue in refractory state and thus could block electrical conduction. 6, 8, 11 Such a 'block of electrical activity' mechanism is suggested by our data showing the ability to block atrial electrical activity by epicardial illumination ( Figure 4B and C) , which indicates sufficient light penetration throughout the atrial wall. Although this mechanism requires higher light intensity compared with pacing and filling of excitable gaps ( Figure 4C) , it does not require to analyse the underlying re-entry wavefront which would simplify devices and makes AF termination more robust. In line with these considerations, we found robust optogenetic AF termination with success rates of up to 97% when using illumination durations longer than one AF cycle length ( Figure 3C ) and when using the high light intensities required to block atrial activity ( Figure 4B and C). This 'block of electrical activity' mechanism is also well in line with our recent findings in simulations of optogenetic defibrillation in a human heart by sustained depolarization of all myocardial layers. 11 Although we cannot discriminate between the 'filling of excitable gap' and the 'block of electrical activity' mechanism in each AF termination event, our data strongly suggest that the latter mechanism will add to the efficacy of AF termination. Importantly, this effect can only be achieved by an optogenetic method allowing constant and homogenous depolarization and tissue refractoriness by illumination. In the future, local brief illumination triggered by local electrograms will be useful to identify novel illumination patterns to fill the excitable gaps for efficient cardioversion and thereby might provide also insights to optimize low energy electrical cardioversion strategies. [23] [24] [25] Furthermore, the ability of optogenetic methods to induce uniform de-and hyperpolarization 5 as well as the use of spatial and temporal defined illumination patterns opens up new avenues to understand the mechanisms underlying AF induction, maintenance and cardioversion. Importantly light stimulation can be feed-back controlled by electrical or contractile activity and this would allow an in-depth interrogation with the biological system, a technology which was shown before by spatially dynamic precise optogenetic modulation of re-entrant wavefronts and rotors in a two dimensional cardiac tissue. 26 Excitingly, we were also able to prove optogenetic termination of AF in wild type hearts up to 8 months after one single AAV injection. In light of recent successful optogenetic defibrillation with blue light in mouse 11, 27 and rat hearts 21 whose ventricles have comparable myocardial wall thicknesses to human atria, 28 especially in patients with AF, 29 our results raise hope for a possible clinical alternative to electrical shocks. Optogenetic cardioversion could offer pain-free AF termination, since illumination does not activate sensory or pain neurons when ChR2 is selectively expressed in cardiomyocytes. Importantly light itself does not induce considerable heat production during continuous illumination even when using light intensities much higher than the ones used in our study. 30, 31 However, cardiac specific expression of ChR2 is pivotal, which can be achieved by selective tropism of the AAV towards cardiomyocytes and by expression driven by myocardial specific promotors. Such cardiomyocyte specific overexpression has been recently optimized using the cardiac Troponin T promoter and AAV with the serotype 9 capsid. 32, 33 For optogenetic termination of AF only, without requirement for ventricular defibrillation or pacing, atrial-specific ChR2 expression could be sufficient using the sarcolipin promoter. 34 Alternatively, also the promotors of atrial natriuretic peptide 35 or Cx40 36 could be used, with the draw back that the former is upregulated in failing ventricular myocardium 37 and the latter is also expressed in the cardiac conduction system and endothelial cells. However, despite the safety of AAV cardiac gene delivery, 38 long-term expression and potential activation of the immune system by the nonmammalian ChR2 have to be carefully evaluated and strategies must be optimized to circumvent immune reactions towards ChR2 or AAV. This is of special concern as we found a low level of immune cell infiltration in the AAV transduced hearts. However it is known that the immune response can vary dramatically between species. 39 Furthermore, mouse models are suited for prove-of-concept studies but provide limited translational evidence considering the complex pathophysiology of AF and atrial anatomy in humans. 40 These include differences in atrial ionic currents and Ca 2þ handling, ectopic electrical activity from the pulmonary veins as well as electrical and structural remodeling in AF patients. 41, 42 Importantly, limiting
ChR2 expression to cardiomyocytes could likely impede the efficacy of optogenetic cardioversion in patients with a high level of atrial fibrosis. This could be addressed by overexpressing ChR2 in fibroblasts and cardiomyocytes given an electrical coupling between both cell types. 43 Thus, the promising results of our proof-of-concept study have to be verified in pre-clinical large animal models with human-like anatomy and comparable atrial arrhythmia. Such animal models will not only allow predicting the therapeutic value of optogenetic cardioversion but will also be of great value to solve open questions on progressive AF disease mechanisms such as AF begetting AF 18 by performing repetitive cardioversions on demand with implanted light sources. Cardiac illumination could be achieved by the recent developments in implantable optoelectronics, such as cell-scale injectable LEDs, [44] [45] [46] LEDs integrated in stretchable integumentary membranes 47 and mLED arrays. 48 Taken together, the herein presented first prove of shock-less cardioversion by light in explanted hearts and mice in vivo could lay the foundation for future developments towards implantable optical cardioverters as a novel therapeutic option for patients with AF. 
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